Protego's $130M Bet on a New Class of Protein Degraders

The strategic significance of Protego Biopharma's $130M Series B lies in the high-stakes race to validate next-generation protein degraders. The company is advancing a platform of heterobifunctional PROTACs (Proteolysis Targeting Chimeras) designed to eliminate disease-causing proteins previously considered 'undruggable' with small molecules. This capital will directly fund the Phase 1/2 trial for its lead asset, PGB-101, a degrader targeting a key transcription factor in autoimmune disease, and advance its oncology pipeline, including a KRAS-G12C degrader program. The competitive landscape is dense with pioneers like Arvinas and Kymera Therapeutics, but Protego differentiates through its proprietary E3 ligase recruiter library and a focus on transcription factors, a challenging target class that could unlock new biology. The market opportunity is substantial, as successful degraders in oncology and immunology could command multi-billion dollar valuations by addressing profound unmet needs in resistant cancers and refractory autoimmune conditions. The outlook hinges on clinical data; key milestones to watch are initial safety and pharmacodynamic data from the PGB-101 trial in 2026 and the nomination of a development candidate from its KRAS program. This financing enables the critical transition from platform validation to clinical proof-of-concept, a defining phase for the entire protein degrader field.